Investigation of Neurological Disease Pathophysiology Using Fluorine-18-Labeled SMBT-1 PET

Investigation of Neurological Disease Pathophysiology Using Fluorine-18-Labeled SMBT-1 PET - Investigation of Neurological Disease Pathophysiology Using Fluorine-18-Labeled SMBT-1 PET

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000061096

Enrollment

500

Registered

2026-03-29

Start date

2026-03-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurological disorder

Interventions

Fluorine-18-labeled SMBT-1 will be intravenously administered at a dose of 3-5 MBq/kg and PET/CT imaging of the brain will be performed for 20 minutes beginning 50 minutes after injection.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: neurological disorder

Exclusion criteria

Exclusion criteria: articipants meeting any of the following criteria will be excluded: Patients who are pregnant or may be pregnant Patients with an urgent and life-threatening condition Patients deemed unsuitable for the study by the investigator

Design outcomes

Primary

Measure	Time frame
SMBT-1 uptake on fluorine-18-labeled PET quantified as the standardized uptake value	—

Countries

Japan

Contacts

Public ContactYuka yamamoto

Faculty of Medicine, Kagawa University Radiology

yamamoto.yuka@kagawa-u.ac.jp087-898-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026